Related Experiment Videos
Drug mechanisms in anxiety
1Address JE 2029 Neurobiologie de l'Anxiété et de la Depression, Faculté de Médecine, Nantes, France. mbourin@sante.univ-nantes.fr
Current Opinion in Investigational Drugs (London, England : 2000)
|January 31, 2002
Summary
Selective benzodiazepine (BZD) compounds offer a path to avoid drug dependency in anxiety treatment. Research explores alternative therapies like SSRIs and novel receptor agonists for improved anxiety management.
Area of Science:
- Neuroscience
- Pharmacology
- Psychiatry
Background:
- Benzodiazepines (BZDs) are common anxiety treatments but carry risks of drug-induced dependency.
- Developing more selective BZD compounds, like 2,3-substituted BZDs, may mitigate dependency issues.
- Alternative therapeutic strategies are crucial for managing anxiety disorders.
Purpose of the Study:
- To review current and emerging therapeutic approaches for anxiety disorders.
- To highlight the potential of selective BZD analogs and alternative drug classes.
- To identify novel targets for anxiolytic drug development.
Main Methods:
- Literature review of established and investigational anxiety treatments.
- Analysis of pharmacological mechanisms for various drug classes.
- Synthesis of findings on receptor agonists, antagonists, and modulators.
Main Results:
- Selective BZD compounds show promise in reducing dependency.
- Antidepressants like SSRIs are effective for generalized anxiety disorder (GAD).
- Investigational therapies include mGluR2 agonists, CRF antagonists, 5-HT receptor modulators, and CCK2 antagonists.
Conclusions:
- Novel therapeutic strategies beyond traditional benzodiazepines are vital for anxiety treatment.
- Targeting specific receptors and neurotransmitter systems offers promising avenues for anxiolytic drug discovery.
- Further research into selective BZDs and alternative agents is warranted to improve patient outcomes and minimize side effects.